OKUR Stock — OnKure Therapeutics Inc.: Cash, EV, Pipeline

Share price

$2.95

Market cap

$119.5M

Cash

$176.4M

Enterprise value

-$56.9M

Balance sheet

Cash	$176.4M
Debt	$0.0M
Net cash	$176.4M
Enterprise value	-$56.9M
Basic shares	49.9M shares
Fully diluted shares	44.6M shares
Fully diluted market cap	$131.6M
Cash per share	$3.54

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading OKUR daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 11 - Mar 25	OKI-219	Phase 1	Advanced Cancer; Breast Cancer; Advanced Solid Tumors	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

OKI-345

Preclinical · Active Modality: small molecule (next-generation PI3Kα pan-mutant inhibitor)

Target PI3Kα (mutant)

Indications

Breast cancer (Preclinical)

Catalysts

— H1 2027

Status note Designed to selectively inhibit mutant PI3Kα across all hotspot mutations while sparing wild-type PI3Kα.

OKI-355

Preclinical · Active Modality: small molecule (next-generation PI3Kα pan-mutant inhibitor)

Target PI3Kα (mutant)

Indications

Vascular anomalies (Preclinical)

Catalysts

— H1 2027

Status note Designed to selectively inhibit mutant PI3Kα across all hotspot mutations while sparing wild-type PI3Kα.

OKI-219

Phase 1 · Active Modality: small molecule (mutant-selective PI3Kα inhibitor)

Target PI3Kα H1047R (mutant)

Indications

Solid tumors including PI3KαH1047R-mutant breast cancer (Phase 1)

Status note Former lead candidate; first-in-human Phase 1 PIKture-01 trial (monotherapy and combination arms). Excluded from the 2026 Private Placement R&D spend, which funds only the vascular anomalies and breast cancer (OKI-345/355) programs.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	OKI-219
Lead indication	Advanced Cancer
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06239467	Phase 1	Active, not recruiting	Sponsor	OnKure, Inc.	—	Advanced Cancer; Breast Cancer; Advanced Solid Tumors	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for OnKure, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	2,238,684	-196,257	0.48%	2026-08-14
Logos Global Management	963,855	+963,855	0.19%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

OKUR — OnKure Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders